Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...

Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical ...

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil ...

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised RNA-based cancer vaccine with a payment of $250 million. It is the first time that Merck has ...

Gardasil, a vaccine that prevents cancers caused by human papillomavirus has faced declining sales in China, a key market for the product. Merck's shipping pause aims to reduce excess inventory and ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Jan 18 (Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los ...

He also is pushing back against suggestions that the the lawsuit is "anti-vaccine.” Baum said Merck failed to properly warn patients of potential side effects. In a statement on the civil ...

infectious diseases and vaccines, Global Clinical Development, Merck Research Laboratories. "This positive opinion is yet another testament to the clinical profile of CAPVAXIVE and brings us a ...

Merck (MRK) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, recommended ...